Trial Profile

A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 05 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entinostat (Primary) ; Enzalutamide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions
Sponsors Syndax Pharmaceuticals

Most Recent Events

01 Dec 2021 Results published in the Oncologist
26 Jul 2021 Status changed from recruiting to discontinued.
13 Feb 2021 Results (n=6) presented at the 2021 Genitourinary Cancers Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com